Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/ImClone's Erbitux Wholesale List Price Will Be $2,400 Per Dose

This article was originally published in The Pink Sheet Daily

Executive Summary

The colorectal cancer therapy will be available to patients Feb. 25. Bristol will use its Oncology Therapeutic Network subsidiary as Erbitux' single-source distributor.

You may also be interested in...



Erbitux Gets C-Code Reimbursement; Waits For Green Light On J-Code

ImClone has not seen "obstacles" to reimbursement across all patients. During the quarter, Erbitux generated $17.5 mil. in sales.

Erbitux Gets C-Code Reimbursement; Waits For Green Light On J-Code

ImClone has not seen "obstacles" to reimbursement across all patients. During the quarter, Erbitux generated $17.5 mil. in sales.

Bristol/ImClone's Erbitux Clears FDA; Undergoing Two Confirmatory Trials

Erbitux is indicated for treatment of EGFR-expressing, metastatic colorectal carcinoma in combination with irinotecan or as monotherapy. Launch is expected within two weeks using product manufactured at Lonza Biologics facility.

Related Content

Topics

UsernamePublicRestriction

Register

PS058674

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel